Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer
Not Applicable
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Other: phenelzine treatment
- Registration Number
- NCT02153281
- Lead Sponsor
- Centre for Addiction and Mental Health
- Brief Summary
The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.
- Detailed Description
Subjects will receive a PET and MRI scan before and after treatment with phenelzine.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- 18-80 years of age
- good physical health
- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE)
- DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation
- greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
- history of non-response to several different antidepressant classes
Exclusion Criteria
- herbal, drug or medication use (that affect CNS function)
- suicide attempts
- drug or medication use within eight weeks (+5 half lives of medication)
- history of substance abuse or any neurotoxin use
- history of psychotic symptoms
- history of central nervous system (CNS) medical illness
- current substance abuse
- test positive on pregnancy test (for women)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Phenelzine treatment phenelzine treatment Subjects will undergo a PET and MRI scan before and after the treatment.
- Primary Outcome Measures
Name Time Method MAO-B VT levels measured with PET in MDE secondary to MDD 8 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Center for Addiction and Mental Health
🇨🇦Toronto, Ontario, Canada